CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 265 enrolled
Drug / intervention
INV-202 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05514548
NCT05514548Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients With Diabetic Kidney Disease

Inversago Pharma Inc.·interventional·Posted Aug 24, 2022·Updated Aug 11, 2025

In Brief

A Phase 2 clinical trial evaluating INV-202 and Placebo for Diabetic Kidney Disease. Completed, enrolled 265 participants across 72 sites in 7 countries.

Detailed Summary

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Kidney Disease
CountriesCanada, Georgia, Hungary, Israel, Mexico, Serbia, United States
CollaboratorsWorldwide Clinical Trials

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedAug 24, 2022
Enrollment StartOct 19, 2022
Primary CompletionAug 20, 2024
Study CompletionSep 3, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.9 years ago

Interventions

INV-202drug

INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.

Placebodrug

Placebo Matching size and number of tablets